ATRC Overview

AtriCure, Inc. provides technologies for the treatment for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management. The Company's cardiac ablation and left atrial appendage management (LAAM) products are used by physicians during open-heart and minimally invasive surgical procedures. Its pain management solutions are used by physicians to freeze nerves during cardiothoracic or thoracic surgical procedures. The Company's products for open and minimally invasive ablation include Isolator Synergy Clamps and Multifunctional Pens and Linear Ablation Devices. Its products for open ablation include cryoICE Cryoablation System. Its products for minimally invasive ablation include EPi-Sense Guided Coagulation System with VisiTrax Technology. Its appendage management products include AtriClip System. The Isolator Synergy Ablation System clamps are single-use disposable radio frequency (RF) products with jaws that close in a parallel fashion.

Wall Street analysts forecast ATRC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ATRC is52.20 USD with a low forecast of 45.00 USD and a high forecast of 64.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

AtriCure Inc revenue for the last quarter amounts to 140.50M USD, increased 13.05

AtriCure Inc. EPS for the last quarter amounts to 0.04 USD, decreased -112.12

AtriCure Inc (ATRC) has 1350 emplpoyees as of March 11 2026.

Today ATRC has the market capitalization of 1.45B USD.